{"analyses":[{"ciLowerLimit":"0.678","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.962","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0169","paramType":"Hazard Ratio (HR)","paramValue":"0.807","statisticalComment":"Adjusted for stratification factors: geographic region, time-to-progression from start of first-line therapy and disease measurability.","statisticalMethod":"Stratified Log Rank Test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.5","upperLimit":"10.8","value":"9.6"},{"groupId":"OG001","lowerLimit":"6.3","upperLimit":"8.4","value":"7.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"330"},{"groupId":"OG001","value":"335"}],"units":"Participants"}],"description":"OS time was measured from date of randomization to date of death from any cause. Participants who were not known to have died on or before the date of data cut-off, OS data was censored on the last date (on or before the cut-off date) the participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"8 mg/kg of ramucirumab (IMC-1121B) was administered by IV infusion on Days 1 and 15 in combination with 80 mg/m² paclitaxel administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle.","id":"OG000","title":"Ramucirumab (IMC-1211B) Plus Paclitaxel"},{"description":"Placebo was administered by IV infusion on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered on Days 1, 8, and 15 of a 28-day cycle.","id":"OG001","title":"Placebo Plus Paclitaxel"}],"paramType":"MEDIAN","populationDescription":"All participants according to the treatment group to which they were randomized. Participants censored: Ramucirumab (IMC-1211B) plus Paclitaxel =74, Placebo plus Paclitaxel =75.","reportingStatus":"POSTED","timeFrame":"Randomization up to 27.5 months","title":"Overall Survival Time (OS)","type":"PRIMARY","unitOfMeasure":"months"}